Table 6.

HCV genotype (GT)-4, GT-5 and GT-6 SVR12 from different regimens

Genotype	Company	Regimen	Non-cirrhotic (LSM < 14.7 kPa)	Cirrhotic (LSM ≥ 14.7 kPa)
			SVR12 (%)/number of treated patients
GT-4	AbbVie	Ombitasvir plus paritaprevir, 12 weeks	91 % (41/44, treatment-naïve) [81]	No data available
		Ombitasvir plus paritaprevir plus RBV, 12 weeks	100 % (42/42, treatment-naïve or experienced) [81]	No data yet (study is on-going)
	Gilead	Ledipasvir and sofosbuvir (Harvoni™), 12 Weeks	95 % [19/20, treatment-naïve (62 %) or experienced (38 %)] [80]	No data available
		Sofosbuvir plus velpatasvir	100 % (116/116, Sofosbuvir plus velpatasvir 12 weeks) [ASTRAL-1 study] [86]	83 % (75/90, GT1-6, Sofosbuvir plus velpatasvir 12 weeks) [ASTRAL-4 study] [86] 94 % (82/87, GT1-6, Sofosbuvir plus velpatasvir plus ribavirin (RBV) 12 weeks) [ASTRAL-4 study] [86] 86 % (77/90, GT1-6, Sofosbuvir plus velpatasvir 24 weeks) [ASTRAL-4 study] [86]
	MSD	Grazoprevir plus elbasvir	100 % (18/18) [253]
GT-5	Gilead	Sofosbuvir plus velpatasvir	97 % (34/35, Sofosbuvir plus velpatasvir 12 weeks) [ASTRAL-1 study] [86]	83 % (75/90, GT1-6, Sofosbuvir plus Velpatasvir 12 weeks) [ASTRAL-4 study] [86] 94 % (82/87, GT1-6, Sofosbuvir plus Velpatasvir plus RBV 12 weeks) [ASTRAL-4 study] [86] 86 % (77/90, GT1-6, Sofosbuvir plus Velpatasvir 24 weeks) [ASTRAL-4 study] [86]
GT-6	Gilead	Ledipasvir and sofosbuvir (Harvoni™)	96 % [24/25, treatment-naïve: 23 (92 %); experienced:2 (8 %); Cirrhosis: (8 %)] [80]
		Sofosbuvir plus velpatasvir	100 % (41/41, Sofosbuvir plus velpatasvir 12 weeks) [ASTRAL-1 study] [86]	83 % (75/90, GT1-6, Sofosbuvir plus velpatasvir 12 weeks) [ASTRAL-4 study] [86] 94 % (82/87, GT1-6, Sofosbuvir plus velpatasvir + RBV 12 weeks) [ASTRAL-4 study] [86] 86 % (77/90, GT1-6, Sofosbuvir plus velpatasvir 24 weeks) [ASTRAL-4 study] [86]